Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

1.

Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy.

Kioi M, Takahashi S, Kawakami M, Kawakami K, Kreitman RJ, Puri RK.

Cancer Res. 2005 Sep 15;65(18):8388-96.

PMID:
16166317
[PubMed - indexed for MEDLINE]
Free Article
2.

Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy.

Kawakami K, Kawakami M, Puri RK.

Crit Rev Immunol. 2001;21(1-3):299-310. Review.

PMID:
11642612
[PubMed - indexed for MEDLINE]
3.

Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.

Husain SR, Puri RK.

J Neurooncol. 2003 Oct;65(1):37-48. Review.

PMID:
14649884
[PubMed - indexed for MEDLINE]
4.

Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma.

Puri RK.

Toxicol Pathol. 1999 Jan-Feb;27(1):53-7. Review.

PMID:
10367674
[PubMed - indexed for MEDLINE]
Free Article
5.

A review of studies on targeting interleukin 4 receptor for central nervous system malignancy.

Puri S, Puri S, Mahapatra AK, Hussain E, Sarkar C, Sinha S, Joshi BH.

Curr Mol Med. 2009 Aug;9(6):732-9. Review.

PMID:
19689300
[PubMed - indexed for MEDLINE]
6.

Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.

Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK.

Technol Cancer Res Treat. 2006 Jun;5(3):239-50. Review.

PMID:
16700620
[PubMed - indexed for MEDLINE]
7.

Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.

Kawakami M, Kawakami K, Puri RK.

J Neurooncol. 2003 Oct;65(1):15-25. Review.

PMID:
14649882
[PubMed - indexed for MEDLINE]
8.

Tumor-targeting amino acid auxotrophic Salmonella typhimurium.

Hoffman RM.

Amino Acids. 2009 Sep;37(3):509-21. doi: 10.1007/s00726-009-0261-8. Epub 2009 Mar 17. Review.

PMID:
19291366
[PubMed - indexed for MEDLINE]
9.

Cytokine receptor as a sensitizer for targeted cancer therapy.

Kawakami K, Kawakami M, Puri RK.

Anticancer Drugs. 2002 Aug;13(7):693-9. Review.

PMID:
12187325
[PubMed - indexed for MEDLINE]
10.

Cintredekin besudotox in treatment of malignant glioma.

Mut M, Sherman JH, Shaffrey ME, Schiff D.

Expert Opin Biol Ther. 2008 Jun;8(6):805-12. doi: 10.1517/14712598.8.6.805 . Review.

PMID:
18476792
[PubMed - indexed for MEDLINE]
11.

Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer.

Dijkgraaf EM, Welters MJ, Nortier JW, van der Burg SH, Kroep JR.

Curr Pharm Des. 2012;18(25):3816-27. Review.

PMID:
22591418
[PubMed - indexed for MEDLINE]
12.

Technology evaluation: cintredekin besudotox, NeoPharm/Nippon.

Rainov NG, Söling A.

Curr Opin Mol Ther. 2005 Apr;7(2):170-81. Review.

PMID:
15844626
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk